Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Globe and Mail, The (Toronto, Canada)]
Erasca, Inc. (ERAS)
Company Research
Source: Globe and Mail, The
Shares fell after the company disclosed a patient death from pneumonitis in its ERAS-0015 trial. Investors are watching for clearer safety data. Trading volume reached 51 million shares, about 709% above its three-month average of 6.3 million shares. Erasca IPO'd in 2021 and has fallen 43% since going public. How the markets moved today The S&P 500 slipped 0.48% to 7,139, while the Nasdaq Composite lost 0.90% to finish at 24,664. Among biotechnology stocks, peer Revolution Medicines closed at $144.83, up 10%, as investors weighed divergent trial headlines across cancer-drug developers. What this means for investors Erasca disclosed a potentially treatment-related death in its Phase 1 ERAS-0015 trial, and its stock plummeted 48% on the unfortunate news. However, while initial reports label the passing “treatment-related,” many analysts and Erasca's management are pushing back on this notion. One J.P. Morgan analyst explained it was “more of a one-off case versus a clear drug-re
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca stock sinks 50% after patient death in drug trial [Yahoo! Finance]Yahoo! Finance
- Patient Death Drags Erasca (ERAS) Shares by 48% [Yahoo! Finance]Yahoo! Finance
- Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial [Yahoo! Finance]Yahoo! Finance
- Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight [Seeking Alpha]Seeking Alpha
- Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 4/28/26 - Form ARS
- 4/28/26 - Form DEFA14A
- 4/28/26 - Form DEF
- ERAS's page on the SEC website